Biohaven Pharmaceutical (NYSE:BHVN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Monday. The firm currently has a $25.00 target price on the stock. Zacks Investment Research‘s price objective would suggest a potential upside of 10.72% from the stock’s previous close.

According to Zacks, “Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company’s pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. “

A number of other research analysts have also issued reports on BHVN. BidaskClub raised Biohaven Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 7th. Piper Jaffray Companies reissued a “buy” rating and issued a $54.00 target price on shares of Biohaven Pharmaceutical in a report on Tuesday, September 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $43.00 price objective (up previously from $30.00) on shares of Biohaven Pharmaceutical in a report on Wednesday, September 13th. Morgan Stanley upped their price objective on Biohaven Pharmaceutical from $28.00 to $47.00 and gave the stock an “overweight” rating in a report on Monday, September 25th. Finally, William Blair reaffirmed an “outperform” rating on shares of Biohaven Pharmaceutical in a report on Tuesday, October 3rd. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $38.17.

Biohaven Pharmaceutical (BHVN) traded down $0.55 during trading hours on Monday, hitting $22.58. The stock had a trading volume of 579,300 shares, compared to its average volume of 211,629. Biohaven Pharmaceutical has a 1-year low of $17.00 and a 1-year high of $39.51.

In related news, Director Gregory Bailey sold 9,970 shares of the stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $25.48, for a total transaction of $254,035.60. Following the transaction, the director now directly owns 1,262,759 shares in the company, valued at $32,175,099.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Vlad Coric sold 150,000 shares of the stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $29.41, for a total value of $4,411,500.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 434,131 shares of company stock worth $11,901,751.

A number of large investors have recently made changes to their positions in BHVN. VHCP Management II LLC acquired a new stake in Biohaven Pharmaceutical during the third quarter worth about $60,826,000. Eagle Asset Management Inc. acquired a new stake in shares of Biohaven Pharmaceutical in the third quarter valued at about $32,635,000. Janus Henderson Group PLC acquired a new stake in shares of Biohaven Pharmaceutical in the third quarter valued at about $25,751,000. JPMorgan Chase & Co. acquired a new stake in shares of Biohaven Pharmaceutical in the third quarter valued at about $18,173,000. Finally, Stifel Financial Corp acquired a new stake in shares of Biohaven Pharmaceutical in the third quarter valued at about $15,525,000. Institutional investors own 47.76% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/04/biohaven-pharmaceutical-bhvn-raised-to-buy-at-zacks-investment-research.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Analyst Recommendations for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Stock Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related stocks with our FREE daily email newsletter.